Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorGuihua Wang

About this trial

We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer

Eligibility criteria

Qualifiers

The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;

Age 18-75 years old (at the time of signing the informed consent), both male and female;

Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;

Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;

Disqualifiers

The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;

Age 18-75 years old (at the time of signing the informed consent), both male and female;

Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;

Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;

Trial design

Treatments tested in this trial

  • Proximal radical gastrectomy
  • Total radical gastrectomy

Treatment groups

404 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Guihua Wang

Lead sponsor

Tongji Hospital

Sponsor institution

Fudan University

Collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator

Xiangya Hospital of Central South University

Collaborator

Shandong First Medical University

Collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator

The First Medical Center of Chinese PLA General Hospital

Collaborator

Affiliated Hospital of Qinghai University

Collaborator

Qilu Hospital of Shandong University

Collaborator

Ruijin Hospital

Collaborator

First Affiliated Hospital, Sun Yat-Sen University

Collaborator

Southern Medical University, China

Collaborator

Shanxi Bethune Hospital

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

The Third Xiangya Hospital of Central South University

Collaborator

Jingzhou Central Hospital

Collaborator

Xiangyang Central Hospital

Collaborator

Yichang Central People's Hospital

Collaborator

The First Affiliated Hospital of University of South China

Collaborator

Guangdong Provincial People's Hospital

Collaborator

People's Hospital of Macheng City

Collaborator

Southwest Hospital, China

Collaborator

Liaoning Cancer Hospital & Institute

Collaborator

RenJi Hospital

Collaborator

Changhai Hospital

Collaborator

The First Affilated Hospital of the Medical College, Shihezi University

Collaborator

First Affiliated Hospital Xi'an Jiaotong University

Collaborator

First Affiliated Hospital of Xinjiang Medical University

Collaborator

Sixth Affiliated Hospital, Sun Yat-sen University

Collaborator

First Hospital of China Medical University

Collaborator

Shanghai East Hospital

Collaborator

General Hospital of Ningxia Medical University

Collaborator

Shanghai Changzheng Hospital

Collaborator